The outbreak of coronavirus disease 2019(COVID-19)is a global pandemic.Many clinical trials have been performed to investigate potential treatments or vaccines for this disease to reduce the high morbidity and mortali...The outbreak of coronavirus disease 2019(COVID-19)is a global pandemic.Many clinical trials have been performed to investigate potential treatments or vaccines for this disease to reduce the high morbidity and mortality.The drugs of higher interest include umifenovir,bromhexine,remdesivir,lopinavir/ritonavir,steroid,tocilizumab,interferon alpha or beta,ribavirin,fivapiravir,nitazoxanide,ivermectin,molnupiravir,hydroxychloroquine/chloroquine alone or in combination with azithromycin,and baricitinib.Gastrointestinal(GI)symptoms and liver dysfunction are frequently seen in patients with COVID-19,which can make it difficult to differentiate disease manifestations from treatment adverse effects.GI symptoms of COVID-19 include anorexia,dyspepsia,nausea,vomiting,diarrhea and abdominal pain.Liver injury can be a result of systemic inflammation or cytokine storm,or due to the adverse drug effects in patients who have been receiving different treatments.Regular monitoring of liver function should be performed.COVID-19 vaccines have been rapidly developed with different technologies including mRNA,viral vectors,inactivated viruses,recombinant DNA,protein subunits and live attenuated viruses.Patients with chronic liver disease or inflammatory bowel disease and liver transplant recipients are encouraged to receive vaccination as the benefits outweigh the risks.Vaccination against COVID-19 is also recommended to family members and healthcare professionals caring for these patients to reduce exposure to the severe acute respiratory syndrome coronavirus 2 virus.展开更多
Gastroesophageal reflux disease is one of most common causes of chronic cough.Medical history offers few clues as to the cause of cough induced by this disease.24-h esophageal ph monitoring is considered as the most s...Gastroesophageal reflux disease is one of most common causes of chronic cough.Medical history offers few clues as to the cause of cough induced by this disease.24-h esophageal ph monitoring is considered as the most sensitive and specific test for the diagnosis.When it is unavailable or unsuitable,upper gastrointestinal endoscopy and barium esophagography can be used as an alternative examination.Combined multichannel intraluminal impedance and pH testing is promising because of its ability to detect nonacid reflux as well as acid reflux.Empiric therapy trial is a simple and cheap way to identify suspected patients.Drug therapy is effective in most of the patients,in which proton pump inhibitors is the most powerful.Antireflux surgery is the last choice,used only when intensive drug therapy fails.The definitive diagnosis of cough due to gastroesophageal reflux disease can be established only after cough improves or completely disappears with antireflux therapy.展开更多
In this study, chronic-type rabbit hemorrhagic disease occurred in rabbit warrens of Shandong, Liaoning, Beijing and Hebei, which was mainly charac-terized by deaths of young and adult rabbits, longer durationand nerv...In this study, chronic-type rabbit hemorrhagic disease occurred in rabbit warrens of Shandong, Liaoning, Beijing and Hebei, which was mainly charac-terized by deaths of young and adult rabbits, longer durationand nerve symptoms, was surveyed by epidemiological investigation, bacterial isolation and incubation, artificial infection test and histopathologieal method to analyze the causes of chronic-type rabbit hemorrhagic disease and put forward the corresponding control measures.展开更多
Chronic kidney disease(CKD)poses a great burden to global public health as current therapies are generally ineffective.Early detection and effective therapy are crucial for the future prevention and progression of CKD...Chronic kidney disease(CKD)poses a great burden to global public health as current therapies are generally ineffective.Early detection and effective therapy are crucial for the future prevention and progression of CKD.Nanoparticles(NPs)vary by particle size,charge,shape and the density of targeting ligands and are associated with enhancement of the pharmacokinetic properties,targetability,or the bioavailability of drugs.Thus,the emergence of NPs in medicine has provided novel solutions to the potential diagnosis and treatment of CKD.This review describes the current experimental research,clinical applications of NPs,the current challenges,and upcoming opportunities in the diagnosis and treatment of CKD.展开更多
近期,美国心脏协会(American Heart Association,AHA)、美国心脏病学会(American College of Cardiology,ACC)等六大学会联合发布了《2023 AHA/ACC/ACCP/ASPC/NLA/PCNA慢性冠状动脉疾病患者管理指南》,该指南强调了“以患者为中心,以团...近期,美国心脏协会(American Heart Association,AHA)、美国心脏病学会(American College of Cardiology,ACC)等六大学会联合发布了《2023 AHA/ACC/ACCP/ASPC/NLA/PCNA慢性冠状动脉疾病患者管理指南》,该指南强调了“以患者为中心,以团队为基础”的总体管理理念和重视生活方式改善对慢性冠状动脉疾病患者预后的影响,并对主要心血管不良事件风险评估及新型药物推荐等作出了新的阐述,指南内容的更新对于指导我国临床医生为慢性冠状动脉疾病患者提供高质量管理具有重要指导意义。展开更多
This paper mainly analyzes the application status of TCM rehabilitation in chronic obstructive pulmonary disease(COPD),hoping to provide support and help for clinical staff through this study,and promote the further d...This paper mainly analyzes the application status of TCM rehabilitation in chronic obstructive pulmonary disease(COPD),hoping to provide support and help for clinical staff through this study,and promote the further development of COPD rehabilitation program.展开更多
文摘The outbreak of coronavirus disease 2019(COVID-19)is a global pandemic.Many clinical trials have been performed to investigate potential treatments or vaccines for this disease to reduce the high morbidity and mortality.The drugs of higher interest include umifenovir,bromhexine,remdesivir,lopinavir/ritonavir,steroid,tocilizumab,interferon alpha or beta,ribavirin,fivapiravir,nitazoxanide,ivermectin,molnupiravir,hydroxychloroquine/chloroquine alone or in combination with azithromycin,and baricitinib.Gastrointestinal(GI)symptoms and liver dysfunction are frequently seen in patients with COVID-19,which can make it difficult to differentiate disease manifestations from treatment adverse effects.GI symptoms of COVID-19 include anorexia,dyspepsia,nausea,vomiting,diarrhea and abdominal pain.Liver injury can be a result of systemic inflammation or cytokine storm,or due to the adverse drug effects in patients who have been receiving different treatments.Regular monitoring of liver function should be performed.COVID-19 vaccines have been rapidly developed with different technologies including mRNA,viral vectors,inactivated viruses,recombinant DNA,protein subunits and live attenuated viruses.Patients with chronic liver disease or inflammatory bowel disease and liver transplant recipients are encouraged to receive vaccination as the benefits outweigh the risks.Vaccination against COVID-19 is also recommended to family members and healthcare professionals caring for these patients to reduce exposure to the severe acute respiratory syndrome coronavirus 2 virus.
文摘Gastroesophageal reflux disease is one of most common causes of chronic cough.Medical history offers few clues as to the cause of cough induced by this disease.24-h esophageal ph monitoring is considered as the most sensitive and specific test for the diagnosis.When it is unavailable or unsuitable,upper gastrointestinal endoscopy and barium esophagography can be used as an alternative examination.Combined multichannel intraluminal impedance and pH testing is promising because of its ability to detect nonacid reflux as well as acid reflux.Empiric therapy trial is a simple and cheap way to identify suspected patients.Drug therapy is effective in most of the patients,in which proton pump inhibitors is the most powerful.Antireflux surgery is the last choice,used only when intensive drug therapy fails.The definitive diagnosis of cough due to gastroesophageal reflux disease can be established only after cough improves or completely disappears with antireflux therapy.
基金Supported by China Spark Program(2015GA620002)Science and Technology Support Program of Science and Technology Department of Hebei Province(14826613D)+1 种基金Project of Qinhuangdao Academy of Agricultural Sciences(2014-04)Project of Qinhuangdao Science and Technology Bureau(201502A054)
文摘In this study, chronic-type rabbit hemorrhagic disease occurred in rabbit warrens of Shandong, Liaoning, Beijing and Hebei, which was mainly charac-terized by deaths of young and adult rabbits, longer durationand nerve symptoms, was surveyed by epidemiological investigation, bacterial isolation and incubation, artificial infection test and histopathologieal method to analyze the causes of chronic-type rabbit hemorrhagic disease and put forward the corresponding control measures.
基金supported by grants from the National Key R&D Program of China(2018YFC2000400)National Natural Science Foundation of China(81570605,81770674,81670651,and 81970573).
文摘Chronic kidney disease(CKD)poses a great burden to global public health as current therapies are generally ineffective.Early detection and effective therapy are crucial for the future prevention and progression of CKD.Nanoparticles(NPs)vary by particle size,charge,shape and the density of targeting ligands and are associated with enhancement of the pharmacokinetic properties,targetability,or the bioavailability of drugs.Thus,the emergence of NPs in medicine has provided novel solutions to the potential diagnosis and treatment of CKD.This review describes the current experimental research,clinical applications of NPs,the current challenges,and upcoming opportunities in the diagnosis and treatment of CKD.
文摘近期,美国心脏协会(American Heart Association,AHA)、美国心脏病学会(American College of Cardiology,ACC)等六大学会联合发布了《2023 AHA/ACC/ACCP/ASPC/NLA/PCNA慢性冠状动脉疾病患者管理指南》,该指南强调了“以患者为中心,以团队为基础”的总体管理理念和重视生活方式改善对慢性冠状动脉疾病患者预后的影响,并对主要心血管不良事件风险评估及新型药物推荐等作出了新的阐述,指南内容的更新对于指导我国临床医生为慢性冠状动脉疾病患者提供高质量管理具有重要指导意义。
基金Supported by Special Research Project of Science and Technology Bureau of Nanchong City,Sichuan Province"Effects of TCM Nursing Based on Syndrome Differentiation on Pulmonary Function and Quality of Life in Patients with Acute Exacerbation of COPD" (22YYJCYJ0057).
文摘This paper mainly analyzes the application status of TCM rehabilitation in chronic obstructive pulmonary disease(COPD),hoping to provide support and help for clinical staff through this study,and promote the further development of COPD rehabilitation program.